Drug Trial Radar · NCT06311682
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
195
Planned (sponsor's estimate)
Start
Jun 10, 2024
Primary completion
Oct 16, 2026
Study completion Apr 28, 2028
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Mar 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections \[SC\]) in combination with topical corticosteroids (TCS) is safe and effective to treat moderate-to-severe atopic dermatitis (AD) in children and infants. This will be judged by a range of assessments that rate the severity and extent of atopic dermatitis and its symptoms, as well as general health status and quality of life. The trial will last for up to 4 years. There will be visits every 2 weeks for the first year and every 6 weeks thereafter. Some of the visits will be conducted by phone. The study involves two different age groups: children aged 2 to under 12 years and infants aged 6 months to under 2 years. This trial compares tralokinumab +TCS to placebo + TCS for children with moderate-to-severe AD and evaluates tralokinumab + TCS for infants with moderate-to-severe AD. Infants will not receive placebo. All subjects will go through a screening process, which is the first part of the trial and will last up to 4 weeks. During this period, it will be checked if the child or infant meets the criteria to participate in the trial. The children will be randomly assigned to receive tralokinumab + TCS or placebo + TCS for the initial 16 weeks, with the treatment being double-blinded. During the first 16 weeks, children will have a 2 out of 3 chance of getting tralokinumab and a 1 out of 3 chance of getting placebo. Thereafter, all subjects will receive tralokinumab + TCS. The infants will receive tralokinumab + TCS as open-label treatment for the entire treatment period, meaning that the participants will know they are receiving tralokinumab. After stopping treatment, all participants will enter a 4-week safety follow-up period.
Conditions
- Atopic Dermatitis
Interventions
Tralokinumab + TCSDrug
The trial medication will be given under the skin (SC). Dose and dosing frequency for each subject will depend on the subject's body weight. Subjects who will receive treatment every two weeks will receive a loading dose corresponding to a double dose at baseline. Subjects who will receive treatment every 4 weeks will receive a staggered loading dose at baseline and Week 2. After the loading dose, they will continue to receive treatment every 4 weeks. The dose and dosing frequency will be adjusted according to the subject's body weight at weeks 16, 32, 52, 64, 88, 112, 136, 160, and 184.
Placebo + TCSDrug
The trial medication will be given under the skin (SC). Dose and dosing frequency for each subject will depend on the subject's body weight. Subjects who will receive treatment every two weeks will receive a loading dose corresponding to a double dose at baseline. Subjects who will receive treatment every 4 weeks will receive a staggered loading dose at baseline and Week 2. After the loading dose, they will continue to receive treatment every 4 weeks. The dose and dosing frequency will be adjusted according to the subject's body weight at weeks 16, 32, 52, 64, 88, 112, 136, 160, and 184.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator's Global Assessment for atopic dermatitis (IGA 0/1) score of 0 (clear) or 1 (almost clear) in subjects aged 2 to <12 years at screening.Time frame: At week 16
- Having at least 75% reduction in Eczema Area and Severity Index (EASI) score in subjects aged 2 to <12 years at screening.Time frame: At week 16
Locations
72 sites in 13 countries. Site status is shown where the registry gives one.
Leo Pharma Investigational site
Birmingham, Alabama · Recruiting
Leo Pharma Investigational site
North Little Rock, Arkansas · Recruiting
Leo Pharma Investigational site
Palo Alto, California · Recruiting
Leo Pharma Investigational site
Sacramento, California · Recruiting
Leo Pharma Investigational site
San Diego, California · Withdrawn
Leo Pharma Investigational site
San Diego, California · Recruiting
Leo Pharma Investigational site
Jacksonville, Florida · Recruiting
Leo Pharma Investigational site
Miami, Florida · Recruiting
Leo Pharma Investigational site
Tampa, Florida · Recruiting
Leo Pharma Investigational site
Macon, Georgia · Recruiting
Leo Pharma Investigational site
Waterford, Michigan · Recruiting
Leo Pharma Investigational site
Tulsa, Oklahoma · Recruiting
Leo Pharma Investigational site
Portland, Oregon · Recruiting
Leo Pharma Investigational site
Charleston, South Carolina · Recruiting
Leo Pharma Investigational site
Norfolk, Virginia · Recruiting
Leo Pharma Investigational site
Brussels, Belgium · Withdrawn
Leo Pharma Investigational site
Ghent, Belgium · Active not recruiting
Leo Pharma Investigational site
Leuven, Belgium · Withdrawn
Leo Pharma Investigational site
Liège, Belgium · Withdrawn
Leo Pharma Investigational site
Burlington, Canada · Recruiting
Leo Pharma Investigational site
Calgary, Canada · Withdrawn
Leo Pharma Investigational site
Calgary, Canada · Recruiting
Leo Pharma Investigational site
Edmonton, Canada · Recruiting
Leo Pharma Investigational site
Edmonton, Canada · Recruiting
Leo Pharma Investigational site
Hamilton, Canada · Recruiting
Leo Pharma Investigational site
Niagara Falls, Canada · Recruiting
Leo Pharma Investigational site
Saskatoon, Canada · Recruiting
Leo Pharma Investigational site
Windsor, Canada · Recruiting
Leo Pharma Investigational site
Winnipeg, Canada · Recruiting
Leo Pharma Investigational site
Rijeka, Croatia · Active not recruiting
Leo Pharma Investigational site
Zagreb, Croatia · Active not recruiting
Leo Pharma Investigational site
Zagreb, Croatia · Withdrawn
Leo Pharma Investigational site
Buxtehude, Germany · Withdrawn
Leo Pharma Investigational site
Dresden, Germany · Withdrawn
Leo Pharma Investigational site
Mainz, Germany · Withdrawn
Leo Pharma Investigational site
Osnabrück, Germany · Withdrawn
Leo Pharma Investigational site
Tübingen, Germany · Active not recruiting
Leo Pharma Investigational site
Wuppertal, Germany · Withdrawn
Leo Pharma Investigational site
Cork, Ireland · Active not recruiting
Leo Pharma Investigational site
Crumlin, Ireland · Active not recruiting
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.